EcoDrugPlus

Tubulin, Alpha 1a

Ensembl ID : ENSBTAG00000001489
Gene Symbol: TUBA1A
64 Enzyme and pathways 4 Cross references
101 Possible Orthologues:

Tubulin, Alpha 1b

Ensembl ID : ENSBTAG00000012244
Gene Symbol: TUBA1B
4 Cross references
92 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSBTAG00000001069
Gene Symbol: TP53
44 Enzyme and pathways 5 Cross references
266 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSBTAG00000011813
Gene Symbol: TYR
3 Enzyme and pathways 5 Cross references
278 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSBTAG00000026768
Gene Symbol: TH
4 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSBTAG00000011698
Gene Symbol: TYK2
26 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSBTAG00000003777
Gene Symbol: TIE1
5 Cross references
217 Possible Orthologues:

Utrophin

Ensembl ID : ENSBTAG00000009665
Gene Symbol: UTRN
5 Cross references
268 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSBTAG00000005339
Gene Symbol: VEGFA
11 Enzyme and pathways 5 Cross references
266 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSBTAG00000016414
Gene Symbol: VDR
13 Enzyme and pathways 5 Cross references
478 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSBTAG00000000405
Gene Symbol: VKORC1
4 Enzyme and pathways 4 Cross references
201 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSBTAG00000012519
Gene Symbol: XDH
9 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).